United Therapeutics Reports ‘Solid’ Fourth Quarter As Inhaled Remodulin Gains Fans
This article was originally published in The Pink Sheet Daily
Executive Summary
Look for NDA filing for Viveta in June, approval in first half of 2009, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
United Therapeutics Replaces Oral Treprostinil With Lilly’s Tadalafil In PAH – For Now
Non-shocking Phase III blowup coincides with U.S. deal for rights to drug already cleared for erectile dysfunction.
United Therapeutics Replaces Oral Treprostinil With Lilly’s Tadalafil In PAH – For Now
Non-shocking Phase III blowup coincides with U.S. deal for rights to drug already cleared for erectile dysfunction.
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.